Cargando…

A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium. Hydroxyurea has been p...

Descripción completa

Detalles Bibliográficos
Autores principales:	McArthur, James G., Svenstrup, Niels, Chen, Chunsheng, Fricot, Aurelie, Carvalho, Caroline, Nguyen, Julia, Nguyen, Phong, Parachikova, Anna, Abdulla, Fuad, Vercellotti, Gregory M., Hermine, Olivier, Edwards, Dave, Ribeil, Jean-Antoine, Belcher, John D., Maciel, Thiago T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049346/ https://www.ncbi.nlm.nih.gov/pubmed/31147439 http://dx.doi.org/10.3324/haematol.2018.213462

Ejemplares similares

The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-ĸB Activation in Transgenic Sickle Mice
por: Belcher, John D., et al.
Publicado: (2015)

Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction
por: Belcher, John D., et al.
Publicado: (2018)

Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia
por: Belcher, John D., et al.
Publicado: (2018)

Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells
por: Zhang, Ping, et al.
Publicado: (2021)

Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease
por: Beckman, Joan D., et al.
Publicado: (2021)

The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease
por: Belcher, John D., et al.
Publicado: (2023)

H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
por: Vercellotti, Gregory M., et al.
Publicado: (2014)

Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence
por: Gentinetta, Thomas, et al.
Publicado: (2022)

Innate immune cells, major protagonists of sickle cell disease pathophysiology
por: Allali, Slimane, et al.
Publicado: (2020)

Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1–42‐mediated cytotoxicity
por: Cameron, Ryan T., et al.
Publicado: (2016)

β-Globin Sleeping Beauty Transposon Reduces Red Blood Cell Sickling in a Patient-Derived CD34(+)-Based In Vitro Model
por: Sjeklocha, Lucas M., et al.
Publicado: (2013)

Correction: β-Globin Sleeping Beauty Transposon Reduces Red Blood Cell Sickling in a Patient-Derived CD34(+)-Based In Vitro Model
por: Sjeklocha, Lucas M., et al.
Publicado: (2014)

P-006: SICKLE RED BLOOD CELL (RBC)-DERIVED EXTRACELLULAR VESICLES ACTIVATE ENDOTHELIAL CELLS AND ENHANCE SICKLE RBC ADHESION MEDIATED BY VON WILLEBRAND FACTOR
por: R., AN, et al.
Publicado: (2022)

Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease
por: Hebbel, Robert P., et al.
Publicado: (2021)

Innate-like T cells in children with sickle cell disease
por: Allali, Slimane, et al.
Publicado: (2019)

Substituted spirooxindole derivatives as potent anticancer agents through inhibition of phosphodiesterase 1
por: Barakat, Assem, et al.
Publicado: (2018)

Vasculotoxic and Proinflammatory Effects of Plasma Heme: Cell Signaling and Cytoprotective Responses
por: Belcher, John D., et al.
Publicado: (2013)

A monocyte‐TNF‐endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade
por: Solovey, Anna, et al.
Publicado: (2017)

Potent In Vitro Phosphodiesterase 1 Inhibition of Flavone Isolated from Pistacia integerrima Galls
por: Rauf, Abdur, et al.
Publicado: (2022)

Primary Hyperparathyroidism in Sickle Cell Disease: An Unknown Complication of the Disease in Adulthood
por: Denoix, Elsa, et al.
Publicado: (2020)

Evidence for complement-mediated bone marrow necrosis in a young adult with sickle cell disease
por: Azul, Melissa, et al.
Publicado: (2021)

Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition
por: Sun, Liping, et al.
Publicado: (2014)

SGK1 inhibition induces fetal hemoglobin expression and delays polymerization in sickle erythroid cells
por: Hara, Yannis, et al.
Publicado: (2023)

The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
por: Ding, Pei-Rong, et al.
Publicado: (2011)

Identification of a Heme Activation Site on the MD-2/TLR4 Complex
por: Belcher, John D., et al.
Publicado: (2020)

O-11: AUTOMATED QUANTIFICATION OF POCKED RED BLOOD CELLS CORRELATES WITH SPLEEN SIZE IN SICKLE CELL DISEASE
por: A., SISSOKO, et al.
Publicado: (2022)

3D-QSAR Study of Potent Inhibitors of Phosphodiesterase-4 Using a CoMFA Approach
por: Yang, Zhaoqi, et al.
Publicado: (2007)

A preliminary study of phosphodiesterases and adenylyl cyclase signaling pathway on red blood cell deformability of sickle cell patients
por: Goksel, Evrim, et al.
Publicado: (2023)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

Brachial plexitis: an unusual presentation in sickle cell disease
por: Dawood, Mustafa, et al.
Publicado: (2019)

Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5
por: Chau, Yasmin, et al.
Publicado: (2019)

P1496: OPERATOR-INDEPENDENT, FLUORESCENCE-BASED QUANTIFICATION OF POCKED RED CELLS CORRELATES WITH SPLEEN SIZE AND FUNCTION IN SICKLE CELL DISEASE
por: Sissoko, A., et al.
Publicado: (2022)

Care of the Critically Ill Pediatric Sickle Cell Patient
por: Rosanwo, Tolulope, et al.
Publicado: (2018)

Transfusion‐related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory
por: Ribeil, Jean‐Antoine, et al.
Publicado: (2018)

P-061: DE NOVO APPEARANCE OF VACUOLES IN TRANSFUSED RED BLOOD CELLS IN SICKLE CELL DISEASE PATIENTS WITH DEFECTIVE SPLENIC FUNCTION
por: L., DUMAS, et al.
Publicado: (2022)

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
por: Lagresle-Peyrou, Chantal, et al.
Publicado: (2018)

Hesperidin-3′-O-Methylether Is More Potent than Hesperidin in Phosphodiesterase Inhibition and Suppression of Ovalbumin-Induced Airway Hyperresponsiveness
por: Yang, You-Lan, et al.
Publicado: (2012)

Potent Phosphodiesterase Inhibition and Nitric Oxide Release Stimulation of Anti-Impotence Thai Medicinal Plants from “MANOSROI III” Database
por: Manosroi, Aranya, et al.
Publicado: (2017)

The role of mast cells in cancers
por: Maciel, Thiago T., et al.
Publicado: (2015)

Sickle Cell Trait Modulates the Proteome and Phosphoproteome of Plasmodium falciparum-Infected Erythrocytes
por: Chauvet, Margaux, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iuhcd0l9d63m5q20l32mltbuu8